Caldan Therapeutics Announces Key Appointments and a Collaboration With Sygnature Discovery
In All, PortfolioCaldan Therapeutics, a spin-out company from the Universities of Glasgow and Southern Denmark, which specialises in developing novel therapeutics targeting free fatty acid receptors for the treatment of metabolic disease, including Type 2 Diabetes, is pleased to announce the following appointments: Dr Frank M Armstrong…